Study of quality of life in patients with moderate to severe plaque psoriasis treated by infliximab
LIU Yong-hua
Abstract：Objective To study the influence factors of quality of life in patients with moderate to severe plaque psoriasis treated by infliximab. Method A total of 31 patients with moderate to severe plaque psoriasis were observed. These patients were treated by infliximab. PASI and DLQI were measured before the intervention and 2, 6 and 14 weeks after the intervention. Results The mean PASI score at baseline was (18.48±5.08), after 14 weeks treatment, the mean PASI score changed to (3.03±2.65). DLQI score was (14.74± 4.67) at baseline, after 14 weeks treatment, the mean DLQI score changed to (1.87±1.82). For both the PASI score and the DLQI score, there were statistic difference between before and after treatment(P<0.05). DLQI had correlation with sex, age, degree of education, disease duration and PASI. Stepwise multiple linear regression analysis revealed that PASI and disease duration were predictors of DLQI(P<0.05). Conclusion Infliximab treatment can rapidly reduce the signs and symptoms of psoriasis and improve the lower quality of life in patients with moderate to severe plaque psoriasis. PASI and disease duration are significant predictors of DLQI. The lower PASI and shorter disease duration mean the better quality of life of the patients.
Keywords：PsoriasisInfliximabQuality of lifePASI
Publication Date：2018-01-01
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：4( 282-285 )